I visited Cuba
in 2013. My tour guide was determined for our group to see Cuba as more than a
former haunt of mobsters from the U.S. and a place to see vintage U.S. cars.
She bragged about how Cuba was modernizing its economy. I figured many of her
comments were carefully rehearsed propaganda.
However, one of
her claims caught my attention. She said Cuban researchers had patented a
drug for cancer. When I got home, I checked. Researchers
at the Center of Molecular Immunology in Havana and scientists in Argentina had
developed a therapeutic cancer vaccine, called Racotumomab, to treat one type
of lung cancer (non-small cell lung cancer). A multicenter clinical trail is
now evaluating the drug’s effectiveness.
This drug is an example of a hot area of research
– the development of cancer immunotherapy drugs, sometimes called cancer
vaccines. These drugs rev up a patient’s own immune system to produce cells,
which recognize substances found on the surface of tumor cells but not on the
surface of normal cells. These cells then slay the cancer cells, but not the
normal cells.
Okay that’s a heavy dose of science. Do these drugs work? The
editors of Science named cancer
immunotherapy the “scientific breakthrough of the year” in 2013. Hundred of
labs worldwide are developing and patenting potential drugs of this sort. So
far, none, including the Cuban one, have been a huge success. Several have
helped patients to survive longer in clinical trials.
Why the fuss about this one Cuban patent? This
patent demonstrates Cuban scientists are doing competitive science and
understand the importance of commercialization of their research. I also
discovered Cuban were already visiting American universities, and a number of
U.S. scientists were trying to augment these scientific exchanges despite the
U.S. embargo on Cuba.
I thought this could be the basis of a novel.
Realistically the State Department might send (in the near future) scientists
to Cuba to explore the possibility of creating government-sponsored exchanges
between the two countries. Certainly scientific exchanges between the US and
China were early steps in the normalization of our relationship with China
during the Nixon administration.
The birth of MALIGNANCY: A Novel. I
thought Sara Almquist, the epidemiologist and heroine of my previous medical
thrillers Coming Flu and Ignore the Pain would be the perfect
protagonist to do a little “scientific diplomacy” in Cuba. Besides, I could
throw in a little intrigue about drugs slipping from Bolivia through Cuba and
into the U.S.
Here’s
a blurb on MALIGNANCY. Men disguised as police officers shoot at Sara Almquist
twice in one day. The real police suspect Jim Mazzone, a drug czar who Sara has
tangled with several times, will order more hits on Sara. Thus when colleagues
in the State Department invite Sara to arrange scientific exchanges between the
U.S. and Cuba, she jumps at the chance to get out of town. Maybe, she should
question their motives.
I think you’ll find this novel has plenty of action and deserves thriller status. And it has something no other thriller has – a middle-aged woman heroine.